卡博替尼单药治疗复发性透明细胞卵巢癌、原发性腹膜癌或输卵管癌的II期研究(NRG-GY001)
该II期研究评估卡博替尼单药治疗复发性透明细胞卵巢癌、原发性腹膜癌或输卵管癌的疗效与耐受性,共纳入13例患者,接受卡博替尼60 mg口服每日一次持续给药。结果显示无客观肿瘤缓解,6个月无进展生存率为23%,中位无进展生存期3.6个月,中位总生存期8.1个月,结论为卡博替尼在二线或三线治疗中活性有限。
要点
- 13例复发性透明细胞卵巢癌、原发性腹膜癌或输卵管癌患者接受卡博替尼60 mg每日一次治疗。
- 无客观肿瘤缓解,3例(23%)患者无进展生存期≥6个月。
- 中位无进展生存期3.6个月,中位总生存期8.1个月。
核心结论
- 卡博替尼在复发性透明细胞卵巢癌、输卵管癌或原发性腹膜癌的二线和三线治疗中活性有限。
研究设计与样本
- II期研究,纳入13例复发性卵巢、输卵管或原发性腹膜透明细胞肿瘤(透明细胞组织形态≥50%)患者,既往接受过一或两种方案,ECOG体能状态0-2。
- 患者接受卡博替尼60 mg口服每日一次持续给药,以4周为一周期,直至疾病进展或不可接受的毒性。
- 主要终点为6个月无进展生存率和客观肿瘤缓解(RECIST 1.1评估);次要终点包括毒性、无进展生存期和总生存期。
主要发现
- 在19个月内共入组13例患者,54%的患者年龄≥60岁,体能状态0和1分别有8例和5例。
- 未见客观肿瘤缓解;13例患者中3例(23%[95%CI:5%,54%])无进展生存期≥6个月,其中1例接受卡博替尼23个周期,截至数据截止日期仍在治疗中。
- 中位无进展生存期为3.6个月,中位总生存期为8.1个月。
- 1例患者发生5级事件:血栓栓塞事件被认为可能与研究治疗相关,患者死因确定为疾病和方案治疗。
- 另有4例患者发生血栓栓塞事件(2例3级,1例1级,1例2级);在2例或以上患者中报告的其他3级或以上事件包括恶心、呕吐、疲乏、呼吸困难和脱水。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and tolerability of cabozantinib in recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer. METHODS: Patients with recurrent ovarian, fallopian or primary peritoneal tumors with at least 50% clear cell histomorphology, measurable disease, one or two prior regimens and ECOG performance status 0-2 received cabozantinib 60 mg orally once daily continuously, in 4-week cycles until disease progression or unacceptable toxicity. Primary endpoints were progression-free survival (PFS) at six months and complete or partial tumor response (as assessed by RECIST 1.1). Secondary endpoints included toxicity, PFS, and overall survival (OS). RESULTS: Over 19 months, 13 patients were accrued. Fifty-four percent of patients were ≥60 years of age. Performance statuses of 0 and 1 comprised 8 and 5 patients. No objective tumor responses were seen. Three (23% [95% CI: 5%, 54%]) of 13 patients had PFS ≥6 months, including one patient who received cabozantinib for 23 cycles and was still on treatment as of the data cut-off date. Median PFS and OS were 3.6 and 8.1 months, respectively. There was one patient with a grade 5 event: a thromboembolic event considered possibly related to study therapy; patient's cause of death was determined to be due to disease and protocol treatment. Four other patients had thromboembolic events (two grade 3 and one each grade 1 and grade 2). Other grade 3 or higher events reported in two or more patients were nausea, vomiting, fatigue, dyspnea, and dehydration. CONCLUSIONS: Cabozantinib demonstrated minimal activity in the second- and third-line treatments of clear cell ovarian, fallopian tube or primary peritoneal carcinoma.
引用
- Konstantinopoulos PA, Brady WE, Farley J, et al. Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001). Gynecol Oncol. 2018. PMID: 29739622. doi:10.1016/j.ygyno.2018.04.572
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。